Abstract
Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation. Clinical trials have demonstrated the efficacy of osimertinib in this patient population and clinical trials of other third-generation EGFR TKI are currently under way. Additional challenges in this patient population, such as the upfront efficacy of osimertinib, validation of T790M in liquid biopsies as a dynamic predictive marker of efficacy, along with combination with immune checkpoint inhibitors are being explored, representing an extraordinary time of development for EGFR-mutant NSCLC.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acrylamides / pharmacology
-
Acrylamides / therapeutic use*
-
Aniline Compounds / pharmacology
-
Aniline Compounds / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Clinical Trials as Topic
-
Disease-Free Survival
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
Gain of Function Mutation
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / mortality
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
Substances
-
Acrylamides
-
Aniline Compounds
-
Protein Kinase Inhibitors
-
osimertinib
-
EGFR protein, human
-
ErbB Receptors